NCT06298084View on ClinicalTrials.gov

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

March 21, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

June 30, 2029

Conditions
Breast Cancer MetastaticHER2-positive Metastatic Breast CancerHER2 Low Breast CarcinomaAdvanced Breast Cancer
Interventions
DRUG

Patritumab deruxtecan

5.6 mg/kg every 21 days

DRUG

Olaparib

100 mg b.i.d PO days 8-14 every 21 days

Trial Locations (1)

94805

RECRUITING

Gustave Roussy Institut, Villejuif

Sponsors

Collaborators (1)

Daiichi Sankyo
All Listed Sponsors
collaborator

Daiichi Sankyo

INDUSTRY

lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT06298084 - Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd | Biotech Hunter | Biotech Hunter